Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687327 | 0.79 | HPGD (1.00) | HPGDRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL743611 | 0.79 | HPGD (1.00) | HPGDRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL30678539 | 0.79 | HPGD (1.00) | HPGDRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL16334901 | 0.77 | RAB9A (1.00) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL16333352 | 0.77 | RAB9A (1.00) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL16333354 | 0.77 | RAB9A (1.00) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL12942542 | 0.75 | HPGD (0.64) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL16496127 | 0.74 | HPGD (0.62) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL22573496 | 0.74 | HPGD (0.59) | HPGDRAB9AKMT2ANPC1LMNA | |
| SCHEMBL3460707 | 0.74 | ALDH1A1 (0.58) | HPGDRAB9AKMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2016105477-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLTHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105477-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLTHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, ABCC5, ABCB1 | HPGD 921/4885RAB9A 917/4885KMT2A 3408/4885 |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, ABCC5, ABCB1 | HPGD 921/4885RAB9A 917/4885KMT2A 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.